In a groundbreaking development, researchers in Japan have secured approval for the world’s first drug designed to regrow teeth, paving the way for human trials set to commence in September. If successful, this innovative treatment could be available to consumers by 2030.
The drug, developed by a team led by Katsu Takahashi, head of dentistry and oral surgery at Kitano Hospital, targets the uterine sensitization-associated gene-1 (USAG-1) protein, which inhibits tooth growth. By blocking this protein’s interaction with others, the treatment stimulates bone growth, effectively encouraging the regrowth of teeth.
Early trials in ferrets and mice yielded promising results without any significant side effects, although researchers acknowledge that human physiology differs from these animals. However, they express confidence due to the 97% similarity in the functioning of the USAG-1 protein across species.
The upcoming clinical trial will focus on adults missing at least one molar, while subsequent trials will include children aged two to seven with congenital tooth deficiencies and older adults missing one to five permanent teeth due to environmental factors.
With nearly two decades of research backing this drug, Takahashi and his colleagues remain optimistic, anticipating that by 2030, the need for traditional dental solutions may be dramatically altered, allowing individuals to indulge in sweets without fear of tooth loss—though moderation is still advised. This development is the culmination of years of advancements in dental science, including regenerative fillings and stem cell techniques aimed at repairing and regenerating dental tissues.
You Might Be Interested In
